3 results
Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…
Primary:*To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegalySecondary:*To investigate the safety and tolerability of a single dose of lanreotide PRF…
Aim of the study is to ascertain the order of magnitude to which ESWT may improve the performance of specific activities of daily living (ADL), measured by Goal Entertainment Scaling (GAS) in people with spinal cord injury and spasticity in the…